Fig. 1
Study population and treatment cohorts. Anti-TNFα: anti-tumor necrosis factor alpha; CD: Crohn’s disease; UC: ulcerative colitis; VDZ: vedolizumab
Fig. 1 | BMC Gastroenterology
Study population and treatment cohorts. Anti-TNFα: anti-tumor necrosis factor alpha; CD: Crohn’s disease; UC: ulcerative colitis; VDZ: vedolizumab